{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084860","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-07-20T11:12:37+00:00","discovered_at":"2026-07-20T11:15:00.254350+00:00","generated_at":"2026-07-20T11:15:16.512952+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Armata Pharmaceuticals promotes David House to CFO, effective July 17, 2026","bullets":["David House appointed CFO; previously SVP Finance and principal financial officer since Aug 2024.","Base salary $371,315; target bonus 50% of base; annual equity award target $300,000.","Severance: 12 months base salary on involuntary termination without cause or for good reason.","Change-in-control acceleration: full vesting of time-based equity if termination within 1 month before or 12 months after CIC.","Also amended Pierre Kyme's employment agreement to conform change-in-control definition."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084860","json":"https://secwatch.observer/filing/0001104659-26-084860.json","markdown":"https://secwatch.observer/filing/0001104659-26-084860.md","text":"https://secwatch.observer/filing/0001104659-26-084860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/0001104659-26-084860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/tm2620782d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T11:15:16.512952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}